Saltar al contenido
Merck
  • Carriage and acquisition rates of Clostridium difficile in hospitalized horses, including molecular characterization, multilocus sequence typing and antimicrobial susceptibility of bacterial isolates.

Carriage and acquisition rates of Clostridium difficile in hospitalized horses, including molecular characterization, multilocus sequence typing and antimicrobial susceptibility of bacterial isolates.

Veterinary microbiology (2014-06-05)
C Rodriguez, B Taminiau, B Brévers, V Avesani, J Van Broeck, A A Leroux, H Amory, M Delmée, G Daube
RESUMEN

Clostridium difficile has been identified as a significant agent of diarrhoea and enterocolitis in both foals and adult horses. Hospitalization, antibiotic therapy or changes in diet may contribute to the development of C. difficile infection. Horses admitted to a care unit are therefore at greater risk of being colonized. The aim of this study was to investigate the carriage of C. difficile in hospitalized horses and the possible influence of some risk factors in colonization. During a seven-month period, faecal samples and data relating the clinical history of horses admitted to a veterinary teaching hospital were collected. C. difficile isolates were characterized through toxin profiles, cytotoxicity activity, PCR-ribotyping, antimicrobial resistance and multilocus sequence typing (MLST). Ten isolates were obtained with a total of seven different PCR-ribotypes, including PCR-ribotype 014. Five of them were identified as toxinogenic. A high resistance to gentamicin, clindamycin and ceftiofur was found. MLST revealed four different sequencing types (ST), which included ST11, ST26, ST2 and ST15, and phylogenetic analysis showed that most of the isolates clustered in the same lineage. Clinical history suggests that horses frequently harbour toxigenic and non-toxigenic C. difficile and that in most cases they are colonized regardless of the reason for hospitalization; the development of diarrhoea is more unusual.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Metronidazole, BioXtra
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Vitamin K1, viscous liquid
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Vitamin K1, BioXtra, ≥99.0% (sum of isomers, HPLC), mixture of isomers
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Phylloquinone (K1), analytical standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
USP
Phytonadione, United States Pharmacopeia (USP) Reference Standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Metronidazole, analytical standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Vitamin K1, Pharmaceutical Secondary Standard; Certified Reference Material
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Sigma-Aldrich
Metronidazole, SAJ first grade, ≥99.0%
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Supelco
Metronidazole, VETRANAL®, analytical standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Vitamin K1, European Pharmacopoeia (EP) Reference Standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad
Metronidazole, European Pharmacopoeia (EP) Reference Standard
Número de referencia del producto (SKU)
Tamaño de envase
Disponibilidad
Precio
Cantidad